about
White cell count and platelet count associate with histological alcoholic hepatitis in jaundiced harmful drinkers.Itch and liver: management in primary care.BAT117213: Ileal bile acid transporter (IBAT) inhibition as a treatment for pruritus in primary biliary cirrhosis: study protocol for a randomised controlled trialDrug treatment of pruritus in liver diseases.A systematic approach to the management of cholestatic pruritus in primary biliary cirrhosis.Acetate, the key modulator of inflammatory responses in acute alcoholic hepatitis.Ubiquitin C-terminal hydrolase 1: A novel functional marker for liver myofibroblasts and a therapeutic target in chronic liver diseaseLiver: Can pentoxifylline secure its place in liver therapeutics?Reducing the harm caused by alcohol: a coordinated European response.Effect of ileal bile acid transporter inhibitor GSK2330672 on pruritus in primary biliary cholangitis: a double-blind, randomised, placebo-controlled, crossover, phase 2a study.An 'alcohol contract' has no significant effect on return to drinking after liver transplantation for alcoholic liver disease.The Impact of Autoimmune Hepatitis and its Treatment on Health Utility.Safety, tolerability and pharmacokinetics of GSK3008348, a novel integrin αvβ6 inhibitor, in healthy participants.Safety, Tolerability, Pharmacokinetic and Pharmacodynamic Evaluations Following Single Oral Doses of GSK2330672 in Healthy Japanese VolunteersReal-world data reveal a diagnostic gap in non-alcoholic fatty liver diseaseChange in model for end-stage liver disease score on the transplant waiting list predicts survival in patients undergoing liver transplantationA coffee with your brandy, Sir?Achieving high standards of trainingPruritus Is Common and Undertreated in Patients With Primary Biliary Cholangitis in the United Kingdom
P50
Q34636494-EE069D3E-FBD8-4463-B00C-518285E9E189Q35631405-11067227-CD63-447C-ACA3-77159F4A24F2Q36080972-6A21EDC5-71D8-49F7-993F-F97B3E344B9FQ38592916-FACFCB24-2C6A-47FD-A061-06555ADCF9F5Q38637490-BBE518DF-4AD0-434E-AA02-2F84A82EF861Q39727242-E6E3F7AF-DE78-47B3-A9D5-1BE49DCEE611Q41537028-A325BFCE-F523-418B-860B-90F5475BC7A5Q42839470-3BADD2D8-49D5-45A9-A0A2-B5446666D83CQ46271632-569D71EC-6749-4A39-B856-664DBAF770C7Q47440077-AF13452C-4F8C-40E1-A001-B787AB66FC66Q47915526-AB34D345-A1D7-41F5-9FE2-6558FE7DB9BEQ52583860-091AAC3D-71C8-4B07-8F39-BCF64600721AQ52659102-F3AD79D4-959E-461D-B87F-2D015ABA2C3DQ57117743-24F08B52-922C-4C06-BCE8-98A89B7E3324Q58787282-BF139ECA-1E9D-45C0-BC28-3E1FD03B5843Q79325075-CAF1892D-2B27-41E4-9DE9-B96F83B1E3CFQ80056214-A223DC7D-F20A-4716-8240-BD818FE634EEQ82617791-402F61CF-D929-489F-99C1-0DCA2F9567E5Q90586751-054218BD-A8B0-45F2-82C6-40AD51133659
P50
description
investigador
@es
researcher
@en
name
Stewart Kendrick
@en
Stewart Kendrick
@nl
type
label
Stewart Kendrick
@en
Stewart Kendrick
@nl
prefLabel
Stewart Kendrick
@en
Stewart Kendrick
@nl
P31
P496
0000-0002-0804-5743